Distinct Clinical Characteristics Draw a New Prognostic Model for Splenic Marginal Zone Lymphoma in HBV High Prevalent Region

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 13

PMID 29228725

Citations 5

Authors

Shuhua Yi

Yuting Yan

Wenjie Xiong

Rui Lv

Zhen Yu

Wei Liu

Enbin Liu

Heng Li

Huimin Liu

Zengjun Li

Gang An

Yan Xu

Kun Ru

Dehui Zou

Lugui Qiu

Affiliations

Soon will be listed here.

Abstract

Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell neoplasm with hepatitis virus supposed to involve in the pathogenesis. The characteristics of SMZL derived from Caucasia population and high hepatitis C virus (HCV) infection region have been widely investigated, but few was reported in the Eastern population with HBV prevalent region. We analyzed the clinical characteristics, cytogenetic aberrations and prognostic factors in 160 SMZL patients from China. 25 patients (16%) were HBsAg-positive and 54 (34%) patients with resolved HBV infection. IGH gene usage was analyzed in 39 patients. The preferential usages of IGHV genes were IGHV1-2 (26%), followed by IGHV4-34 (18%) and IGHV2-70 (10%). The patients with HBV infection presented biased IGHV-D-J rearrangements and mutational status. Using three independent factors hemoglobin level, HBsAg positivity and complex karyotype, we developed a new hierarchical prognostic model, which showed a better c-index than the previously reported IIL and HPLL scoring systems in SMZL. In conclusion, SMZL in HBV prevalent region have unique clinical and biological characteristics and new prognostic scoring model should be adopted in this population.

Citing Articles

Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.

Wang J, Yan Y, Xiong W, Song G, Wang Y, Zhao J Blood Adv. 2022; 6(13):4049-4059.

PMID: 35537114 PMC: 9278287. DOI: 10.1182/bloodadvances.2022007279.

The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Nguyen-Khac F, Bidet A, Daudignon A, Lafage-Pochitaloff M, Ameye G, Bilhou-Nabera C Leukemia. 2022; 36(6):1451-1466.

PMID: 35430613 DOI: 10.1038/s41375-022-01561-w.

Emergency Splenectomy in a Patient with Splenic Marginal Zone Lymphoma, Acute Portal Vein Thrombosis, and Chronic Viral Hepatitis B.

Karpova R, Gorbunov A, Mnatsakanyan M, Pogromov A, Sokolova I, Shumskaya Y J Blood Med. 2021; 12:431-434.

PMID: 34135652 PMC: 8200168. DOI: 10.2147/JBM.S283098.

[The prognostic significance of POD24 in 106 cases with splenic marginal lymphoma with bone marrow invasion].

Lyu R, Yan Y, Yi S, Wang T, Deng S, Liu W Zhonghua Xue Ye Xue Za Zhi. 2020; 41(3):228-233.

PMID: 32311893 PMC: 7357934. DOI: 10.3760/cma.j.issn.0253-2727.2020.03.008.

Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B Instead of Hepatitis C Virus as an Etiologic and Possible Prognostic Factor - A Multicenter Cohort Study.

Okay M, Aslan T, Ozdemir E, Uner A, Saglam A, Gungor E Turk J Haematol. 2019; 37(2):84-90.

PMID: 31630512 PMC: 7236417. DOI: 10.4274/tjh.galenos.2019.2019.0177.

References

Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O . Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002; 3(1):41-7. DOI: 10.3816/clm.2002.n.010. View

Parry-Jones N, Matutes E, Gruszka-Westwood A, Swansbury G, Wotherspoon A, Catovsky D . Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003; 120(5):759-64. DOI: 10.1046/j.1365-2141.2003.04165.x. View

Yi S, Zou D, Li C, Zhong S, Chen W, Li Z . High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival. Oncotarget. 2015; 6(39):42362-71. PMC: 4747232. DOI: 10.18632/oncotarget.5705. View

Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M . Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006; 107(12):4643-9. DOI: 10.1182/blood-2005-11-4659. View

Fujimoto K, Endo T, Nishio M, Obara M, Yamaguchi K, Takeda Y . Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier. Int J Hematol. 2009; 90(5):601-604. DOI: 10.1007/s12185-009-0426-y. View

Kalpadakis C, Pangalis G, Angelopoulou M, Sachanas S, Kontopidou F, Yiakoumis X . Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013; 18(2):190-7. PMC: 3579603. DOI: 10.1634/theoncologist.2012-0251. View

Liang X, Bi S, Yang W, Wang L, Cui G, Cui F . Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009; 27(47):6550-7. DOI: 10.1016/j.vaccine.2009.08.048. View

Harrell Jr F, Califf R, Pryor D, Lee K, Rosati R . Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-6. View

Olszewski A . Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol. 2012; 87(11):E119-22. DOI: 10.1002/ajh.23314. View

10.

Kalpadakis C, Pangalis G, Dimitriadou E, Angelopoulou M, Siakantaris M, Kyrtsonis M . Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. Anticancer Res. 2009; 29(5):1811-6. View

11.

Brisou G, Verney A, Wenner T, Baseggio L, Felman P, Callet-Bauchu E . A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. Haematologica. 2014; 99(10):e197-8. PMC: 4181269. DOI: 10.3324/haematol.2014.107680. View

12.

Yi S, Li Z, Zou D, An G, Cui R, Zhong S . Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med. 2016; 19(2):182-191. DOI: 10.1038/gim.2016.81. View

13.

Lenglet J, Traulle C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S . Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma. 2013; 55(8):1854-60. DOI: 10.3109/10428194.2013.861067. View

14.

Perrone S, DElia G, Annechini G, Ferretti A, Tosti M, Foa R . Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leuk Res. 2016; 44:53-60. DOI: 10.1016/j.leukres.2016.03.005. View

15.

Zibellini S, Capello D, Forconi F, Marcatili P, Rossi D, Rattotti S . Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica. 2010; 95(10):1792-6. PMC: 2948108. DOI: 10.3324/haematol.2010.025437. View

16.

Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A . Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2007; 22(3):487-95. DOI: 10.1038/sj.leu.2405068. View

17.

Olszewski A, Ali S . Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2013; 93(3):449-58. DOI: 10.1007/s00277-013-1900-4. View

18.

Yi S, Yu Z, Zhou K, Wang Y, An G, Li Z . TOSO is overexpressed and correlated with disease progression in Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010; 52(1):72-8. DOI: 10.3109/10428194.2010.531411. View

19.

Christou L, Kalambokis G, Bai M, Kamina S, Tsianos E . Splenic marginal zone lymphoma in a patient with chronic hepatitis B. J Gastrointestin Liver Dis. 2010; 18(4):511-2. View

20.

Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse-Glehen A . Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia. 2012; 26(7):1638-46. DOI: 10.1038/leu.2012.3. View